Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Lung cancer is primarily diagnosed during the advanced stage of disease, at which stage
treatment options are severely limited. It is primarily for this reason that lung cancer carries a …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

chemotherapy in terms of PFS, main endpoint of the trial, with 9.7 versus 5.2 months,
respectively (HR 0.37, 95% CI 0.25-0.54). ORRs were 58% and 15%, respectively. OS data …

Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …

Erlotinib (Tarceva™, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the
epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …